Skip to main content

Pharmacology of Glutamate Receptor Antagonists in the Kindling Model

  • Chapter
Kindling 5

Part of the book series: Advances in Behavioral Biology ((ABBI,volume 48))

Abstract

Both decrease in GABAergic inhibition and increase in glutamatergic excitation are thought to be critically involved in the cellular mechanisms underlying the initiation and spread of epileptic seizures and the processes that lead to epileptogenesis and, as a consequence, chronic epilepsy.3,7,8,17,18,31,34 The kindling model of tem oral lobe epilepsy has been particularly helpful in elucidating the important roles of inhibitory and excitatory synaptic function in the development and spread of epileptic activity.34 Based on findings in the kindling and other models of epilepsy, increasing GABAergic transmission and decreasing glutamatergic transmission have been proposed as promising antiepileptic strategies with potential advantages compared with current therapies.17,31 Various drugs which selectively potentiate GABAergic transmission have been developed over the last three to four decades and some of them, e.g. vigabatrin, have recently been marketed for treatment of epilepsy.29 In contrast to the long history of the “GABA hypothesis of epilepsy” and GABAergic drugs developed because of this hypothesis,17 it was not until the development in the early 1980s of subtype-selective excitatory amino acid (EAA) receptor agonists and antagonists that the role of EAA receptor systems in the generation of epileptic activity was fully recognized.34 This initiated an enormous interest in the potential therapeutic use of EAA receptor antagonists in epilepsy and other brain disorders for which an involvement of glutamatergic transmission has been suggested. However, it took several years before systemically active compounds (i.e., compounds which pass the blood-brain-barrier after systemic administration) became available. Furthermore, the vast majority of studies on anticonvulsant effects of such compounds was done in experimental models of acute seizures, while until recently no systematic drug evaluation in chronic models of epilepsy such as kindling was reported.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bacia, T., Szpiro-Zurkowska, A., Bidzinski, J. and Czarkwiani, L. Use of ketamine for activation of EEG and electrocorticographic records in patients with epilepsy, Epilepsia, 30 (1989) 642

    Google Scholar 

  2. Bettler, B. and Mulle, C. Neurotransmitter receptors II: AMPA and kainate receptors, Neuropharmacologv, 34 (1995) 123–139.

    Article  CAS  Google Scholar 

  3. Bradford, H.F. Glutamate, GABA and epilepsy, Progr. Neurobiol. 47 (1995)

    Google Scholar 

  4. Carter, A.J. Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site, Drugs Future, 17 (1992) 595–613.

    Google Scholar 

  5. Carter, A.J. Antagonists of the NMDA receptor-channel complex and motor coordination, Life Sci. 57 (1995) 917–929.

    Article  PubMed  CAS  Google Scholar 

  6. Cotman, C.W., Kahle, J.S., Miller, S.E., Ulas, J. and Bridges, R.J. Excitatory amino acid neurotransmission. In F.E. Bloom and D.J. Kupfer (Eds.) Psychopharmacology. The fourth generation of progress, Raven Press, New York, 1995, pp. 75–85.

    Google Scholar 

  7. Dichter, M.A. Cellular mechanisms of epilepsy and potential new treatment strategies, Epilepsia, 30 (Suppl. 1) (1989) S12

    Google Scholar 

  8. Dingledine, R., McBain, C.J. and McNamara, J.O. Excitatory amino acid receptors in epilepsy, Trends Pharmacol. Sci. 11 (1990) 334–338.

    Article  PubMed  CAS  Google Scholar 

  9. Dziki, M., Hönack, D. and Löscher, W. Kindled rats are more sensitive than non-kindled rats to the behavioural effects of combined treatment with MK-801 and valproate, Eue J. Pharmacol. 222 (1992) 273–278.

    Article  CAS  Google Scholar 

  10. Garcia, Y., Ibarra, C. and Jaffe, E.H. NMDA and non-NMDA receptor-mediated release of [H-3]GABA from granule cell dendrites of rat olfactory bulb, J. Neurochem, 64 (1995) 662–669.

    Article  PubMed  CAS  Google Scholar 

  11. Hönack, D. and Löscher, W. Sex differences in NMDA receptor mediated responses in rats, Brain Res. 620 (1993) 167–170.

    Article  PubMed  Google Scholar 

  12. Johansen, T.H., Drejer, J., Watjen, F. and Nielsen, E.O. A novel non-NMDA receptor antagonist shows selective displacement of low-affinity [3H]kainate binding, Eur. J. Pharmacol. 246 (1993) 195

    Article  PubMed  CAS  Google Scholar 

  13. Jorgensen, M., Tygesen, C.K: and Andersen, P.H. Ionotropic glutamate receptors-focus on non-NMDA receptors, Pharmacol. Toxicol. 76 (1995) 312–319.

    Article  PubMed  CAS  Google Scholar 

  14. Kemp, J.A. and Leeson, P.D. The glycine site of the NMDA receptor-five years on, Trends Pharmacol. Sci. 14 (1994) 20–25.

    Article  Google Scholar 

  15. Koek, W. and Colpaert, F.C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects, J. Pharmacol. Exp. Ther. 252 (1990) 349–357.

    PubMed  CAS  Google Scholar 

  16. Lapin, I.P., Prakhie, I.B. and Kiseleva, I.P. Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: differences between rats and mice, J. Neural Trans. 54 (1982) 229–238.

    Article  CAS  Google Scholar 

  17. Löscher, W. GABA and the epilepsies. Experimental and clinical considerations. In N.G. Bowery and G. Nisticò (Eds.) GABA. Basic research and clinical applications, Pythagora Press, Rome, 1989, pp. 260–300.

    Google Scholar 

  18. Löscher, W. Basic aspects of epilepsy, Curr. Opin. Neurol. Neurosurg. 6 (1993) 223–232.

    PubMed  Google Scholar 

  19. Löscher, W. and Hönack, D. High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats, Naunyn-Schmiedebergs Arch. Pharmacol. 341 (1990) 476–481.

    PubMed  Google Scholar 

  20. Löscher, W. and Hönack, D. Responses to NMDA receptor antagonists altered by epileptogenesis, Trends Pharmacol. Sci. 12 (1991) 52

    Article  PubMed  Google Scholar 

  21. Löscher, W. and Hönack, D. The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotoninl1A receptors, J. Pharmacol. Exp. Ther. 257 (1991) 1146–1153.

    PubMed  Google Scholar 

  22. Löscher, W. and Hönack, D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-Daspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-80I and carbamazepine, J. Pharmacol. Exp. Ther. 256 (1991) 432–440.

    PubMed  Google Scholar 

  23. Löscher, W. and Hönack, D. Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats, Eur J. Pharmacol. 238 (1993) 191–200.

    Article  PubMed  Google Scholar 

  24. Löscher, W. and Hönack, D. Effects of the competitive NMDA receptor antagonist, CGP 37849, on anti-convulsant activity and adverse effects of valproate in amygdala-kindled rats, Eur. J. Pharmacol. 234 (1993) 237–245.

    Article  PubMed  Google Scholar 

  25. Löscher, W. and Hönack, D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats, Eur J. Pharmacol. 259 (1994) R3–R5.

    Article  PubMed  Google Scholar 

  26. Löscher, W., Nolting, B. and Hönack, D. Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital, Eur. J Pharmacol. 152 (1988) 9–17.

    Article  PubMed  Google Scholar 

  27. Löscher, W., Rundfeldt, C. and Hönack, D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy, Eur. J. Neurosci. 5 (1993) 1545–1550.

    Article  PubMed  Google Scholar 

  28. Löscher, W. and Schmidt, D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations, Epilepsy Res. 2 (1988) 145–181.

    Article  PubMed  Google Scholar 

  29. Löscher, W. and Schmidt, D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17 (1994) 95–134.

    Article  PubMed  Google Scholar 

  30. Löscher, W., Wlaz, P., Rundfeldt, C., Baran, H. and Hönack, D. Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats, Brit. J. Pharmacol. 112 (1994) 97–106.

    Article  Google Scholar 

  31. Meldrum, B.S. Excitatory amino acids in epilepsy and potential novel therapies, Epilepsy Res. 12 (1992) 189–196.

    Article  PubMed  CAS  Google Scholar 

  32. Perouansky, M. and Grantyn, R. Is GABA release modulated by presynaptic excitatory amino acid receptors? Neurosci. Lett. 113 (1990) 292–297.

    Article  PubMed  CAS  Google Scholar 

  33. Rogawski, M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines, Trends Pharmacol. Sci. 14 (1993) 325–331.

    Article  PubMed  CAS  Google Scholar 

  34. Rogawski, M.A. Excitatory amino acids and seizures. In T.W. Stone (Ed.) CNS neurotransmitters and neuromodulators: glutamate, CRC Press, Boca Raton, 1995, pp. 219–237.

    Google Scholar 

  35. Rundfeldt, C., Hönack, D. and Löscher, W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats, Neuropharmacology, 29 (1990) 845–851.

    Article  PubMed  CAS  Google Scholar 

  36. Stone, T.W. Subtypes of NMDA receptors, Gen. Pharmacol. (1993) 825–832.

    Google Scholar 

  37. Sveinsbjornsdottir, S., Sander, J.W.A.S., Upton, D., Thompson, P.J., Patsalos, P.N., Hirt, D., Emre, M., Lowe, D. and Duncan, J.S. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy, Epilepsy Res. 16 (1993) 165–174.

    Article  Google Scholar 

  38. Verdoorn, T.A., Johansen, T.H., Drejer, J. and Nielsen, E.O. Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist, Eur. J. Pharmacol. 269 (1994) 43–49.

    Article  PubMed  CAS  Google Scholar 

  39. Wlaz, R, Ebert, U. and Löscher, W. Low doses of the glycine/NMDA receptor antagonist R-(+)-HA-966 but not D-cycloserine induce paroxysmal activity in limbic brain regions of kindled rats, Eur. J. Neurosci. 6 (1994) 1710–1719.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Löscher, W. (1998). Pharmacology of Glutamate Receptor Antagonists in the Kindling Model. In: Corcoran, M.E., Moshé, S.L. (eds) Kindling 5. Advances in Behavioral Biology, vol 48. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5375-5_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5375-5_31

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7453-4

  • Online ISBN: 978-1-4615-5375-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics